High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma

2002 ◽  
Vol 26 (3) ◽  
pp. 241-248 ◽  
Author(s):  
Nozomi Niitsu ◽  
Kimiko Iijima
Keyword(s):  
Hodgkin’S Lymphoma ◽  
High Serum ◽  
Hodgkin's Lymphoma ◽  
Poor Outcome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Soluble Cd44

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4543-4543 ◽  
Author(s):  
Naoe Goto ◽  
Hisashi Tsurumi ◽  
Masao Takemura ◽  
Takeshi Hara ◽  
Michio Sawada ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Serum ◽  
Hodgkin's Lymphoma ◽  
Interleukin 18 ◽  
Ifn Gamma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Interleukin-18 (IL-18), originally designated as an interferon (IFN)-gamma inducing factor, is a cytokine which induces cytotoxic NK cell activity and stimulates T cells to produce IFN-gamma, IL-2, and GM-CSF. Increased serum IL-18 levels have been found in patients with acute lymphoblastic leukemia, chronic myelocytic leukemia, multiple myeloma and non-Hodgkin’s lymphoma (NHL). The aim of the present study was to assess the prognostic significance of serum IL-18 in aggressive NHL. Consecutive 99 previously untreated patients with aggressive NHL (diffuse large B-cell lymphoma; 84 patients, peripheral T-cell lymphoma; 15 patients) prospectively participated in this study between 1997 and 2003. The patients were treated with 6–8 cycles of CHOP or THP (pirarubicin) -COP regimens. To evaluate serum levels of IL-18, venous blood samples were drawn from patients immediately before the initiation of treatment. In all patients with aggressive NHL, the mean ± SD of serum IL-18 level was 1200.8±151.5 pg/ml (range 96–6603.5) with a median of 556.75 pg/ml. Several poor prognostic features such as poor PS, multiple extranodal sites, advanced disease (clinical stage III/IV), existence of B-symptom, and high soluble interleukin-2 receptor (sIL-2R) were strongly associated with a high serum IL-18 levels. An increased LDH and gender were weakly associated with a high serum IL-18. Histology and age were not associated with serum IL-18 levels. The median serum IL-18 levels of the different IPI risk groups were; 321 pg/ml for the L risk; 442 pg/ml for the LI risk; 557 pg/ml for the HI risk; 1532 pg/ml for the H risk, respectively (P<0.005). The CR rate of patients with an IL-18 level of less than 700 pg/ml was better than that of 700 pg/ml or higher (77% and 50%, P<0.01). Patients with high IL-18 (700 pg/ml and over) at onset had a significantly lower survival rate (5-year: 25%) than those with low IL-18 (below 700 pg/ml) (68 %) ( p<0.0001). Multivariate analysis employing IL-18 and some conventional prognostic factors demonstrated that IL-18, performance status and the number of extranodal sites were significantly poor prognostic factors for both overall survival (OS) and event free survival (EFS). The results suggest that a high serum IL-18 level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment.

scholarly journals CXCL12 rs18011157 polymorphısm in patients wıth non-Hodgkin's lymphoma: Is it associated with poor outcome?

2018 ◽  
Vol 14 (5) ◽  
pp. 1075
Author(s):  
GulsumEmel Pamuk ◽  
Hilmi Tozkır ◽  
MehmetSevki Uyanık ◽  
Hakan Gurkan ◽  
Julide Duymaz ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Poor Outcome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma

Blood ◽  
1997 ◽  
Vol 90 (8) ◽  
pp. 3167-3172 ◽  
Author(s):  
Petri Salven ◽  
Lasse Teerenhovi ◽  
Heikki Joensuu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Vascular Endothelial ◽  
Poor Outcome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Endothelial Growth Factor ◽  
Vegf Level

Abstract Vascular endothelial growth factor (VEGF ) is a secreted endothelial cell-specific mitogen, which is induced by hypoxia and is angiogenic in vivo. Recently, elevated serum concentrations of VEGF (S-VEGF ) have been reported in patients with cancers of various histologies. However, the prognostic significance of S-VEGF in human cancer is unknown and the origin of S-VEGF remains unsettled. We measured S-VEGF by enzyme-linked immunosorbent assay from sera taken from 82 patients with non-Hodgkin's lymphoma before treatment and stored for 9 to 15 years at −20°C. All but one of the patients had been followed-up for at least 5 years or until death. S-VEGF ranged from 15 to 964 pg/mL; median, 228 pg/mL; mean, 291 pg/mL. A higher than the median S-VEGF level was associated with a poor World Health Organization performance status, a high International Prognostic Index, a high serum lactate dehydrogenase level, and a large cell histology. Patients with lower than the median S-VEGF at diagnosis had a 71% 5-year survival rate in comparison with only 49% among those with a higher than the median S-VEGF. We conclude that a high pretreatment S-VEGF level is associated with poor outcome in non-Hodgkin's lymphoma.

Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19539-e19539
Author(s):  
A. F. Gharib ◽  
S. A. Eltarhony ◽  
W. H. Elsawy
Keyword(s):  
Hodgkin’S Lymphoma ◽  
International Prognostic Index ◽  
Response To Therapy ◽  
Hodgkin's Lymphoma ◽  
Clinical Value ◽  
Cell Surface Glycoprotein ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Soluble Cd44 ◽  
Hodgkin's Lymphomas

e19539 Background: CD44 is a cell surface glycoprotein expressed by a large variety of tissues. In addition to their expression on the cell membrane, CD44 proteins are also released from cells, and soluble CD44 proteins are detectable in the normal human circulation. The observation that several human tumors show an overexpression of CD44 and the presence of soluble CD44 in the circulation makes CD44 a potential serum marker for tumor detection. In this prospective study, we investigated the prognostic and clinical value of s-CD44 in patients with aggressive non-Hodgkin's lymphomas. Methods: s-CD44 concentration was measured in the sera of 64 patients with aggressive non-Hodgkin's lymphomas treated with standard CHOP by using chemiluminescence-enzyme immunoassay (EIA). Results: Circulating serum CD44 (s-CD44) levels have been found to change in parallel with response to therapy, but little is known about the predictive or prognostic significance of s-CD44. The median pretreatment s-CD44 level was 510 ng/mL(range, 90 to 2,120 ng/mL). Only 10 (31%) of the 32 patients with an International Prognostic Index (IPI) score 0 or 1 had s-CD44 concentration higher than the median level, whereas 11 (52%) of 21 patients with an IPI score ≥2 had a concentration higher than the median before initiation of treatment (P < .0001). Patients with lower than the median s-CD44 achieved more often a complete response to therapy (P = .0002) and had better survival (P = .007) than those with higher s-CD44 levels. However, in a multivariate analysis, only the IPI score had independent prognostic value (P < .001). Conclusions: Our results showed that a high s-CD44 level before treatment is associated with a high IPI score, poor response to treatment, and unfavorable prognosis in aggressive non-Hodgkin's lymphoma. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document